Literature DB >> 12297284

FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation.

E Monsonego-Ornan1, R Adar, E Rom, A Yayon.   

Abstract

A crucial aspect of ligand-mediated receptor activation and shut-down is receptor internalization and degradation. Here we compared the ubiquitylation of either wild type or a K508A 'kinase-dead' mutant of fibroblast growth factor receptor 3 (FGFR3) with that of its naturally occurring overactive mutants, G380R as in achondroplasia, or K650E involved in thanatophoric dysplasia. Fibroblast growth factor receptors ubiquitylation was found to be directly proportional to their intrinsic tyrosine kinase activity, both of which could be blocked using kinase inhibitors. Despite excessive ubiquitylation, both overactive mutants failed to be efficiently degraded, even when challenged with ligand or overexpression of c-Cbl, a putative E3 ligase. We conclude that phosphorylation is essential for FGFR3 ubiquitylation, but is not sufficient to induce downregulation of its internalization resistant mutants.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12297284     DOI: 10.1016/s0014-5793(02)03255-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  24 in total

Review 1.  Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.

Authors:  Silvie Foldynova-Trantirkova; William R Wilcox; Pavel Krejci
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.878

Review 2.  Receptor tyrosine kinase transmembrane domains: Function, dimer structure and dimerization energetics.

Authors:  Edwin Li; Kalina Hristova
Journal:  Cell Adh Migr       Date:  2010-04-23       Impact factor: 3.405

3.  Sprouty 2 disturbs FGFR3 degradation in thanatophoric dysplasia type II: a severe form of human achondroplasia.

Authors:  Changsheng Guo; Catherine R Degnin; Melanie B Laederich; Gregory P Lunstrum; Paul Holden; Jeanie Bihlmaier; Deborah Krakow; Yoon-Jae Cho; William A Horton
Journal:  Cell Signal       Date:  2008-04-10       Impact factor: 4.315

4.  Physical basis behind achondroplasia, the most common form of human dwarfism.

Authors:  Lijuan He; William Horton; Kalina Hristova
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

5.  Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation.

Authors:  Melanie B Laederich; Catherine R Degnin; Gregory P Lunstrum; Paul Holden; William A Horton
Journal:  J Biol Chem       Date:  2011-04-12       Impact factor: 5.157

6.  Effects of diadenosine tetraphosphate on FGF9-induced chloride flux changes in achondroplastic chondrocytes.

Authors:  Fernando Huete; Ana Guzman-Aranguez; Javier Ortín; Charles H V Hoyle; Jesús Pintor
Journal:  Purinergic Signal       Date:  2011-05-11       Impact factor: 3.765

7.  The control of transmembrane helix transverse position in membranes by hydrophilic residues.

Authors:  Shyam S Krishnakumar; Erwin London
Journal:  J Mol Biol       Date:  2007-10-17       Impact factor: 5.469

8.  Tyrosine residues direct the ubiquitination and degradation of the NY-1 hantavirus G1 cytoplasmic tail.

Authors:  Erika Geimonen; Imelyn Fernandez; Irina N Gavrilovskaya; Erich R Mackow
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis.

Authors:  Ellen Margrethe Haugsten; Jedrzej Malecki; Sunniva Maria Stordal Bjørklund; Sjur Olsnes; Jørgen Wesche
Journal:  Mol Biol Cell       Date:  2008-05-14       Impact factor: 4.138

10.  Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner.

Authors:  E di Martino; C G L'Hôte; W Kennedy; D C Tomlinson; M A Knowles
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.